Curaleaf Holdings (CURLF) Net Margin (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Net Margin of 0.09% for Q1 2026, up 323.0% year-on-year from 0.02% in Q1 2025, and up 98.13% on a QoQ basis from 4.84% in Q4 2025.
Curaleaf Holdings (CURLF) Net Margin (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Net Margin for 8 consecutive years, with 0.09% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin rose 323.0% year-over-year to 0.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.64% (down 2.0% YoY) and the FY2025 annual result came in at 2.07%, down 129.0% from the prior year.
- Net Margin improved to 0.09% in Q1 2026 per CURLF's latest filing, from 4.84% in the prior quarter.
- Over the last five years, Net Margin for CURLF reached as high as 20.69% in Q1 2022 and fell as low as 2315585.82% in Q4 2023.
- A 5-year average of 136213.06% and a median of 2.36% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin slumped 231556123 bps — and 2024, when it jumped 231558231 bps.
- Year by year, Net Margin stood at 24.58% in 2022, then sank by 9418984 bps to 2315585.82% in 2023, then jumped by 100 bps to 3.51% in 2024, then plunged by 38 bps to 4.84% in 2025, then soared by 98 bps to 0.09% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 0.09%, 4.84%, and 0.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 35.18% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 4.16% |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | -0.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.09% |
| Dec 31, 2025 | -4.84% |
| Sep 30, 2025 | -0.67% |
| Jun 30, 2025 | -0.96% |
| Mar 31, 2025 | -3.32% |
| Dec 31, 2024 | -3.51% |
| Sep 30, 2024 | 0.49% |
| Jun 30, 2024 | -0.37% |
| Mar 31, 2024 | 0.17% |
| Dec 31, 2023 | -2,315,585.82% |
| Sep 30, 2023 | -7.78% |
| Jun 30, 2023 | -2.36% |
| Mar 31, 2023 | -3.78% |
| Dec 31, 2022 | -24.58% |
| Sep 30, 2022 | -3.92% |
| Jun 30, 2022 | -1.38% |
| Mar 31, 2022 | 20.69% |
| Dec 31, 2021 | -1.70% |
| Sep 30, 2021 | 19.98% |
| Jun 30, 2021 | 24.78% |